Zhen Yu Wong, Pegah Damavandi, Adam Tamas Misky, Jonathan Pollock
{"title":"黑素瘤术前前哨淋巴结活检和淋巴显影的时机:系统回顾和荟萃分析。","authors":"Zhen Yu Wong, Pegah Damavandi, Adam Tamas Misky, Jonathan Pollock","doi":"10.1016/j.bjps.2024.11.062","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The management of malignant melanomas often involves performing a sentinel lymph node biopsy (SLNB) aided by imaging with lymphoscintigraphy. Whether lymphoscintigraphy should be performed on the same day as the SLNB operation (SD) or the day before (DB) surgery remains debated. This study aims to summarise existing evidence regarding the impact of the relative timings of lymphoscintigraphy and SLNB on clinical outcomes in melanoma.</p><p><strong>Methods: </strong>A PRISMA-compliant search was conducted from inception to 28th May 2024. Data were collected on SLNB in melanoma patients who underwent either an SD or DB approach. The following outcomes were extracted from the articles: node identification, recurrence rate and survival outcomes. Pooled effects of outcomes were estimated using the DerSimonian and Laird random-effects model/generalised linear mixed model, where applicable.</p><p><strong>Results: </strong>A total of 9 studies met the inclusion criteria. Six studies (n = 10, 216) compared SD and DB approach outcomes, while 3 studies (n = 153) compared SD and DB SLNB within the same patient cohort. In the former, no significant difference was found in positivity rates between SD and DB groups (RR 1.03, 95% CI 0.94-1.13, p = 0.475), and recurrence rates were comparable (RR 0.90, 95% CI 0.75-1.07, p = 0.233). SD approach was associated with significantly shorter hospital stays and lower costs, but conflicting results were observed in survival outcomes. In the latter studies, all 3 reported discrepancies between the results of the SD and DB approaches.</p><p><strong>Conclusion: </strong>Current evidence is insufficient to provide a definitive answer. Further research is warranted to conclusively evaluate the impact of SLNB timing on melanoma outcomes and patient care.</p>","PeriodicalId":94104,"journal":{"name":"Journal of plastic, reconstructive & aesthetic surgery : JPRAS","volume":"101 ","pages":"196-204"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Timing of sentinel lymph node biopsy and lymphoscintigraphy before surgery for melanoma: A systematic review and meta-analysis.\",\"authors\":\"Zhen Yu Wong, Pegah Damavandi, Adam Tamas Misky, Jonathan Pollock\",\"doi\":\"10.1016/j.bjps.2024.11.062\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The management of malignant melanomas often involves performing a sentinel lymph node biopsy (SLNB) aided by imaging with lymphoscintigraphy. Whether lymphoscintigraphy should be performed on the same day as the SLNB operation (SD) or the day before (DB) surgery remains debated. This study aims to summarise existing evidence regarding the impact of the relative timings of lymphoscintigraphy and SLNB on clinical outcomes in melanoma.</p><p><strong>Methods: </strong>A PRISMA-compliant search was conducted from inception to 28th May 2024. Data were collected on SLNB in melanoma patients who underwent either an SD or DB approach. The following outcomes were extracted from the articles: node identification, recurrence rate and survival outcomes. Pooled effects of outcomes were estimated using the DerSimonian and Laird random-effects model/generalised linear mixed model, where applicable.</p><p><strong>Results: </strong>A total of 9 studies met the inclusion criteria. Six studies (n = 10, 216) compared SD and DB approach outcomes, while 3 studies (n = 153) compared SD and DB SLNB within the same patient cohort. In the former, no significant difference was found in positivity rates between SD and DB groups (RR 1.03, 95% CI 0.94-1.13, p = 0.475), and recurrence rates were comparable (RR 0.90, 95% CI 0.75-1.07, p = 0.233). SD approach was associated with significantly shorter hospital stays and lower costs, but conflicting results were observed in survival outcomes. In the latter studies, all 3 reported discrepancies between the results of the SD and DB approaches.</p><p><strong>Conclusion: </strong>Current evidence is insufficient to provide a definitive answer. Further research is warranted to conclusively evaluate the impact of SLNB timing on melanoma outcomes and patient care.</p>\",\"PeriodicalId\":94104,\"journal\":{\"name\":\"Journal of plastic, reconstructive & aesthetic surgery : JPRAS\",\"volume\":\"101 \",\"pages\":\"196-204\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of plastic, reconstructive & aesthetic surgery : JPRAS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.bjps.2024.11.062\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of plastic, reconstructive & aesthetic surgery : JPRAS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.bjps.2024.11.062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
简介:恶性黑色素瘤的治疗通常包括在淋巴显像辅助下进行前哨淋巴结活检(SLNB)。淋巴显像是否应该在SLNB手术当天(SD)或手术前一天(DB)进行仍有争议。本研究旨在总结有关淋巴显像和SLNB相对时间对黑色素瘤临床结果影响的现有证据。方法:从开始到2024年5月28日进行符合prisma标准的检索。我们收集了接受SD或DB入路的黑色素瘤患者SLNB的数据。以下结果从文章中提取:淋巴结识别,复发率和生存结果。在适用的情况下,使用DerSimonian和Laird随机效应模型/广义线性混合模型估计结果的合并效应。结果:共有9项研究符合纳入标准。6项研究(n = 10,216)比较了SD和DB方法的结果,而3项研究(n = 153)在同一患者队列中比较了SD和DB SLNB。在前者中,SD组和DB组的阳性率无显著性差异(RR 1.03, 95% CI 0.94 ~ 1.13, p = 0.475),复发率具有可比性(RR 0.90, 95% CI 0.75 ~ 1.07, p = 0.233)。SD方法与显著缩短住院时间和降低费用相关,但在生存结果中观察到相互矛盾的结果。在后一项研究中,所有3项研究都报告了SD和DB方法结果之间的差异。结论:目前的证据不足以提供一个明确的答案。需要进一步的研究来最终评估SLNB时间对黑色素瘤预后和患者护理的影响。
Timing of sentinel lymph node biopsy and lymphoscintigraphy before surgery for melanoma: A systematic review and meta-analysis.
Introduction: The management of malignant melanomas often involves performing a sentinel lymph node biopsy (SLNB) aided by imaging with lymphoscintigraphy. Whether lymphoscintigraphy should be performed on the same day as the SLNB operation (SD) or the day before (DB) surgery remains debated. This study aims to summarise existing evidence regarding the impact of the relative timings of lymphoscintigraphy and SLNB on clinical outcomes in melanoma.
Methods: A PRISMA-compliant search was conducted from inception to 28th May 2024. Data were collected on SLNB in melanoma patients who underwent either an SD or DB approach. The following outcomes were extracted from the articles: node identification, recurrence rate and survival outcomes. Pooled effects of outcomes were estimated using the DerSimonian and Laird random-effects model/generalised linear mixed model, where applicable.
Results: A total of 9 studies met the inclusion criteria. Six studies (n = 10, 216) compared SD and DB approach outcomes, while 3 studies (n = 153) compared SD and DB SLNB within the same patient cohort. In the former, no significant difference was found in positivity rates between SD and DB groups (RR 1.03, 95% CI 0.94-1.13, p = 0.475), and recurrence rates were comparable (RR 0.90, 95% CI 0.75-1.07, p = 0.233). SD approach was associated with significantly shorter hospital stays and lower costs, but conflicting results were observed in survival outcomes. In the latter studies, all 3 reported discrepancies between the results of the SD and DB approaches.
Conclusion: Current evidence is insufficient to provide a definitive answer. Further research is warranted to conclusively evaluate the impact of SLNB timing on melanoma outcomes and patient care.